Document Detail


Early response to haloperidol treatment in chronic schizophrenia.
MedLine Citation:
PMID:  8398949     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study examined the time-course of treatment response to haloperidol in chronic schizophrenia. Furthermore the predictive value of baseline psychopathology and early therapeutic changes for the identification of the eventual treatment outcome was examined. After a two-week drug-free period forty-three chronic schizophrenic patients were treated with haloperidol for five weeks. Psychopathology was assessed on the last drug-free day and on the third and eighth day from the initiation of treatment, and then at weekly intervals. At the end of the study based on a priori criteria patients were classified as responders or non-responders to haloperidol. Seventeen patients met criteria for treatment response at the end of five weeks of treatment, while 26 did not. Already by the third day of treatment, in the responders there was a significant decrease in total BPRS and in the subscales scores for psychosis, tension and anergia, but not for hostility-suspiciousness and depression. These decreases represented approximately half of the eventual improvement obtained by the end of the study. Discriminant function analysis showed that severity of symptoms at baseline and improvement by day 3 correctly classified overall outcome in 72% of the cases.
Authors:
R G Stern; R S Kahn; P D Harvey; F Amin; S H Apter; J Hirschowitz
Related Documents :
1354449 - Vapreotide, a somatostatin analogue, in cryptosporidiosis and other aids-related diarrh...
16677149 - Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to i...
10860129 - Long-term patient adherence to antiretroviral therapy.
22203789 - Seasonal abundance and suppression of fruit-piercing moth eudocima phalonia (l.) in a c...
19812449 - Efficacy and safety of darunavir/ritonavir in treatment-experienced hiv type-1 patients...
59189 - Topical therapy of ulcerative herpetic keratitis with human interferon.
18846799 - Percutaneous vertebroplasty in osteoporotic vertebral compression fractures: our initia...
22261489 - Injection augmentation of type 1 laryngeal clefts.
24676549 - Management of a prediabetes case with the dpp-4 inhibitor sitagliptin.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Schizophrenia research     Volume:  10     ISSN:  0920-9964     ISO Abbreviation:  Schizophr. Res.     Publication Date:  1993 Aug 
Date Detail:
Created Date:  1993-11-17     Completed Date:  1993-11-17     Revised Date:  2010-09-02    
Medline Journal Info:
Nlm Unique ID:  8804207     Medline TA:  Schizophr Res     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  165-71     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, Bronx Veteran Administration Medical Center, Mount Sinai School of Medicine, New York, NY 10029.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Chronic Disease
Cohort Studies
Haloperidol / therapeutic use*
Hospitalization
Humans
Male
Middle Aged
Psychiatric Status Rating Scales
Schizophrenia / drug therapy*
Schizophrenic Psychology*
Grant Support
ID/Acronym/Agency:
NIMH RO1 37922-07/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
52-86-8/Haloperidol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Symptom segregation in chronic schizophrenia: the significance of thought disorder.
Next Document:  Schizophrenia, infection and temperature. An animal model for investigating their interrelationships...